Evidence map›Paper›PMID 35560045›Full record

ArticleAmerican journal of hematology2023

Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T-cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurrence after allogeneic stem cell transplant.

David J Gottlieb, Gaurav Sutrave, Wei Jiang, Selmir Avdic, Janine A Street, Renee Simms, Leighton E Clancy, Vicki Antonenas, Brian S Gloss, Caroline Bateman and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Recent developments inMicrobiology and molecular biology reviews : MMBR · 2025
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

David J GottliebBlood Transplant and Cell Therapies Program, Westmead Hospital, Sydney, New South Wales.ORCID 0000-0001-5807-1766
Gaurav SutraveBlood Transplant and Cell Therapies Program, Westmead Hospital, Sydney, New South Wales.
Wei JiangBlood Transplant and Cell Therapies Program, Westmead Hospital, Sydney, New South Wales.
Selmir AvdicSydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales.
Janine A StreetSydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales.
Renee SimmsBlood Transplant and Cell Therapies Program, Westmead Hospital, Sydney, New South Wales.
Leighton E ClancyBlood Transplant and Cell Therapies Program, Westmead Hospital, Sydney, New South Wales.
Vicki AntonenasInstitute of Clinical Pathology and Medical Research, New South Wales Health Pathology, Westmead, New South Wales, Australia.
Brian S GlossWestmead Research Hub, Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
Caroline BatemanSydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales.
David C BishopBlood Transplant and Cell Therapies Program, Westmead Hospital, Sydney, New South Wales.
Kenneth P MicklethwaiteBlood Transplant and Cell Therapies Program, Westmead Hospital, Sydney, New South Wales.
Emily BlythBlood Transplant and Cell Therapies Program, Westmead Hospital, Sydney, New South Wales.
The University of Sydney · AUNew South Wales Department of Health · AUWestmead Institute for Medical Research · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We designed a trial to simultaneously address the problems of graft versus host disease (GVHD), infection, and recurrence of malignancy after allogeneic stem cell transplantation. CD34

Indexed as

Epstein-Barr Virus InfectionsGraft vs Host DiseaseHematopoietic Stem Cell TransplantationPrecursor Cell Lymphoblastic Leukemia-LymphomaHerpesvirus 4, HumanHumansImmunotherapyStem Cell TransplantationT-LymphocytesTransplantation, HomologousTreatment Outcome

Identifiers

PMID35560045
PMCPMC10952473
OpenAlexW4280520984

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.